+1-786-628-7980
Sign Up/Sign In 
Fabry Disease Market Size was valued at USD 2.1 billion in 2022 and is projected to grow from USD 2.26 Billion in 2023 to USD 4.12 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period (2023 – 2032).
Fabry disease, a rare genetic disorder, affects the body’s ability to break down a specific fatty substance. This disorder can lead to severe health issues, including kidney failure, heart problems, and stroke. The Fabry disease market is currently experiencing significant growth due to increased awareness, improved diagnostic techniques, and the development of novel therapies.
The market is driven by several factors, including advancements in genetic research and the introduction of enzyme replacement therapies (ERTs). ERTs, such as agalsidase beta, have become the cornerstone of Fabry disease treatment, significantly improving patient outcomes. Additionally, the emergence of chaperone therapies and gene therapies is expected to further propel market growth.
Get Free Sample PDF Brochure @
https://www.marketresearchfuture.com/sample_request/7064
Market Segmentation
The Fabry Disease Market is a specialized sector within the healthcare industry, focusing on the diagnosis, treatment, and management of Fabry disease. This rare genetic disorder, characterized by a deficiency in the enzyme alpha-galactosidase A, leads to the accumulation of globotriaosylceramide (Gb3) in various body tissues, causing a range of symptoms including pain, kidney dysfunction, heart issues, and strokes.
Market segmentation for the Fabry Disease Market is primarily based on treatment types, including enzyme replacement therapy (ERT), chaperone therapy, and substrate reduction therapy (SRT). ERT currently dominates the market due to its efficacy in replacing the deficient enzyme. However, innovations in chaperone therapy and SRT are gaining traction, offering alternative options for patients who may not respond well to ERT.
Competitive Landscape
Amgen Inc., Amicus Therapeutics Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, iBio, Neuraltus Pharmaceuticals, Novartis AG, Pfizer Inc., AVROBIO, Idorsia Pharmaceuticals Ltd, Protalix, Sanofi, Shire, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.
Regional Analysis
Geographically, the Americas is expected to dominate the global market owing to the increasing technological advancements and rising research and development activities. Gastrointestinal manifestations such as abdominal pain, diarrhea and nausea are significant burden in a patient with Fabry disease. So, for the advanced treatment of these patients SmartPill testing procedure is developed to gain additional understanding of Fabry disease manifestation via motility abnormalities in order to improve symptom targeted therapy. This device is currently under clinical trial and the sponsor of this study is Massachusetts General Hospital.
Browse In-depth Market Research Report (90 Pages) on Fabry Disease:
https://www.marketresearchfuture.com/reports/fabry-disease-market-7064
Europe is expected to hold the second largest market share. Nearly 2.2 in 10,000 people in the European Union (EU) are affected with Fabry disease and Fabrazyme (agalsidase beta), Galafold (migalastat) and Replagal (agalsidase alfa) are the three authorized drugs used for the treatment of Fabry disease.
Discover More Research Reports on Healthcare Industry by Market Research Future:
Asia-Pacific is expected to be the fastest growing market owing to the improving healthcare infrastructure.
Excessive daytime sleepiness Market Research Report Information By Diseases (Obstructive Sleep Apnea (OSA), Narcolepsy), By Treatment (Devices, Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate)) By Distribution channels (Hospitals & Sleep Laboratories, Home Care Settings), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032
DNA Polymerase Market Research Report Information By Type (Taq Polymerase, Pfu Polymerase, Proprietary Enzyme Blends), By Application (Polymerase Chain Reaction, DNA Sequencing, DNA Cloning, SNP Analysis, Next Generation Sequencing), By End-User (Biopharmaceutical Companies, Academic and Research Institutes, Hospitals and Diagnostic Centers, Molecular Diagnostic Companies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032
Europe Clinical Trials Market Research Report Information By Phase (Phase Trial II, Phase III, Phase IV) , By Study Design (Observational, Interventional, Expanded Access), By Application (Pharmaceutical, Medical Devices, Nutrition, Others) By End Users (Hospitals, Home Care, Ambulatory Surgery Centers) By Service Type( Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services, Clinical Trial , Data Management Services), By Country (Germany, France, UK, Italy, Spain, Austria, Rest Of Europe
Pneumonia Testing Market Research Report Information By Product Type (Consumable and Analyzer), By Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluroscence, Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), and Others), By Method Type (Immunodiagnostic, Molecular Diagnostic, and Point-of-Care (POC) Testing), By End-user (Hospitals, Diagnostic Centers, and Others), By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
